Station 4L Lymph Node Dissection: During complete lung resection and systematic mediastinal lymph node dissection, all lymphatic and fatty tissue in the station 4L region is surgically removed and submitted for pathological examination. Other mediastinal stations are dissected according to the study protocol in both arms.
Study summary
This multicenter, prospective, randomized clinical trial will enroll adults aged 18 to 75 years with resectable clinical stage I (T1-T2aN0M0) invasive non-small cell lung cancer presenting as a single solid nodule (consolidation-to-tumor ratio 1.0) in the left lung. After intraoperative frozen-section confirmation of invasive non-small cell lung cancer and completion of standard lung resection and systematic mediastinal lymph node dissection, participants will be randomly assigned 1:1 either to undergo station 4L lymph node dissection or to omit station 4L dissection. The primary hypothesis is that omitting station 4L dissection is noninferior to performing it with respect to 3-year disease-free survival. Secondary outcomes include 3-year overall survival, perioperative complications, 90-day mortality, and station 4L nodal metastasis.
Eligibility
Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria:
* Age 18 to 75 years.
* A single solid pulmonary nodule (consolidation-to-tumor ratio of 1.0) located in the left lung.
* Resectable clinical stage I (T1-T2aN0M0) non-small cell lung cancer, with a maximum tumor diameter of 4 cm or less, evaluated by positron emission tomography/computed tomography.
* Planned complete lung resection by segmentectomy or lobectomy with systematic mediastinal lymph node dissection.
* Intraoperative frozen-section pathological confirmation of invasive non-small cell lung cancer before randomization.
* Able to provide written informed consent and willing to complete the protocol-specified follow-up.
Exclusion Criteria:
* Intraoperative or postoperative pathology indicates noninvasive non-small cell lung cancer.
* Surgical procedure other than segmentectomy or lobectomy.
* Incomplete tumor resection or residual tumor.
* History of another malignant tumor.
* History of previous lung surgery.
* Previous radiotherapy or chemotherapy for the current lung cancer.
Primary outcome measure(s)
3-Year Disease-Free Survival — From enrollment to 3 years Proportion of participants alive without disease recurrence. A disease-free survival event is the first documented recurrence of non-small cell lung cancer or death from any cause.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.